Published online November 19, 2007
Diabetes
57:584-593,
2008
DOI: 10.2337/db07-1414
© 2008 by the American Diabetes Association
Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator- and DUSP14
Sonia Klinger1,2,
Carine Poussin1,2,
Marie-Bernard Debril1,2,
Wanda Dolci1,2,
Philippe A. Halban3, and
Bernard Thorens1,2
1 Institute of Physiology, University of Lausanne, Lausanne, Switzerland
2 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
3 Department of Genetic Medicine and Development, University Medical Center, University Hospital, Geneva, Switzerland
Address correspondence and reprint requests to Bernard Thorens, University of Lausanne, Center for Integrative Genomics, Génopode Building, 1015 Lausanne, Switzerland. E-mail: bernard.thorens{at}unil.ch
Key Words: CREB, cAMP response element-binding protein CREM, cAMP response element modulator DMEM, Dulbecco's modified Eagle's medium ERK1/2, extracellular signal-regulated kinase 1/2 FACS, fluorescence-activated cell sorter FBS, fetal bovine serum GAPDH, glyceraldehyde-3-phosphate dehydrogenase GFP, green fluorescent protein GLP-1, glucagon-like peptide-1 MAPK, mitogen-activated protein kinase PI 3-kinase, phosphatidylinositol 3-kinase PKA, protein kinase A
OBJECTIVE—Glucagon-like peptide-1 (GLP-1) is a growth and differentiation factor for mature β-cells and their precursors. However, the overall effect of GLP-1 on increasing β-cell mass in both in vivo and in vitro conditions is relatively small, and augmenting this effect would be beneficial for the treatment or prevention of type 1 and type 2 diabetes. Here, we searched for cellular mechanisms that may limit the proliferative effect of GLP-1 and tested whether blocking them could increase β-cell proliferation.
RESEARCH DESIGN AND METHODS—We examined GLP-1–regulated genes in βTC-Tet cells by cDNA microarrays. To assess the effect of some of these gene on cell proliferation, we reduced their expression using small heterogenous RNA in β-cell lines and primary mouse islets and measured [3H]thymidine or 5'-bromo-2'-deoxyuridine incorporation.
RESULTS—We identified four negative regulators of intracellular signaling that were rapidly and strongly activated by GLP-1: the regulator of G-protein–signaling RGS2; the cAMP response element-binding protein (CREB) antagonists cAMP response element modulator (CREM)- and ICERI; and the dual specificity phosphatase DUSP14, a negative regulator of the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase 1/2 (ERK1/2) pathway. We show that knockdown of CREM or DUSP14 or expression of a dominant-negative form of DUSP14 increased β-cell line proliferation and enhanced the GLP-1–induced proliferation of primary β-cells.
CONCLUSIONS—Together, our data show that 1) the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control β-cell proliferation, 2) β-cells have evolved several mechanisms limiting GLP-1–induced cellular proliferation, and 3) blocking these mechanisms increases the positive effect of GLP-1 on β-cell mass.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
Related Article:
-
β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
- Frans C. Schuit and Daniel J. Drucker
Diabetes 2008 57: 529-531.
[Extract]
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. C. Schuit and D. J. Drucker
{beta}-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
Diabetes,
March 1, 2008;
57(3):
529 - 531.
[Full Text]
[PDF]
|
 |
|
Copyright © 2008 by the American Diabetes Association.
|
|
| |
|